ES2451653T3 - Dispositivo médico implantable con revestimiento de suministro de fármacos de poliéster de erosión superficial - Google Patents

Dispositivo médico implantable con revestimiento de suministro de fármacos de poliéster de erosión superficial Download PDF

Info

Publication number: ES2451653T3
Authority: ES; Spain
Prior art keywords: poly; lactide; polymer; medical device; implantable medical
Prior art date: 2006-02-10
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

ES07717043.9T

Other languages

English (en)

Spanish (es)

Inventor

Syed Faiyaz Ahmed Hossainy

Stephen D. Pacetti

Murthy V. Simhambhatla

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Abbott Cardiovascular Systems Inc

Original Assignee

Abbott Cardiovascular Systems Inc

Advanced Cardiovascular Systems Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-02-10

Filing date

2007-01-26

Publication date

2014-03-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38284002&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2451653(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-01-26 Application filed by Abbott Cardiovascular Systems Inc, Advanced Cardiovascular Systems Inc filed Critical Abbott Cardiovascular Systems Inc

2014-03-28 Application granted granted Critical

2014-03-28 Publication of ES2451653T3 publication Critical patent/ES2451653T3/es

Status Active legal-status Critical Current

2027-01-26 Anticipated expiration legal-status Critical

Links

239000003814 drug Substances 0.000 title claims abstract description 74
229940079593 drug Drugs 0.000 title claims abstract description 45
230000003628 erosive effect Effects 0.000 title claims abstract description 32
238000000576 coating method Methods 0.000 title description 21
239000011248 coating agent Substances 0.000 title description 19
229920000728 polyester Polymers 0.000 title description 3
229920000642 polymer Polymers 0.000 claims abstract description 117
229940124597 therapeutic agent Drugs 0.000 claims abstract description 29
229920002988 biodegradable polymer Polymers 0.000 claims abstract description 19
239000004621 biodegradable polymer Substances 0.000 claims abstract description 19
229920000249 biocompatible polymer Polymers 0.000 claims abstract description 9
RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 claims description 16
229920001223 polyethylene glycol Polymers 0.000 claims description 14
229920001244 Poly(D,L-lactide) Polymers 0.000 claims description 12
239000003795 chemical substances by application Substances 0.000 claims description 11
JJTUDXZGHPGLLC-ZXZARUISSA-N (3r,6s)-3,6-dimethyl-1,4-dioxane-2,5-dione Chemical compound C[C@H]1OC(=O)[C@H](C)OC1=O JJTUDXZGHPGLLC-ZXZARUISSA-N 0.000 claims description 10
-1 argatrobano Chemical compound 0.000 claims description 10
HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims description 8
229920000954 Polyglycolide Polymers 0.000 claims description 8
RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 claims description 7
229960005167 everolimus Drugs 0.000 claims description 7
229920000669 heparin Polymers 0.000 claims description 7
229960002930 sirolimus Drugs 0.000 claims description 7
IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 claims description 6
OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 claims description 6
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical class OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 6
229920001499 Heparinoid Polymers 0.000 claims description 6
MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims description 6
239000002554 heparinoid Substances 0.000 claims description 6
229940025770 heparinoids Drugs 0.000 claims description 6
WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 claims description 6
229920001432 poly(L-lactide) Polymers 0.000 claims description 6
ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 6
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims description 6
QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 6
108010092160 Dactinomycin Proteins 0.000 claims description 5
108050007372 Fibroblast Growth Factor Proteins 0.000 claims description 5
102000018233 Fibroblast Growth Factor Human genes 0.000 claims description 5
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 5
229960000640 dactinomycin Drugs 0.000 claims description 5
229940126864 fibroblast growth factor Drugs 0.000 claims description 5
229920000052 poly(p-xylylene) Polymers 0.000 claims description 5
229920002307 Dextran Polymers 0.000 claims description 4
VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims description 4
239000005977 Ethylene Substances 0.000 claims description 4
229920000331 Polyhydroxybutyrate Polymers 0.000 claims description 4
230000001028 anti-proliverative effect Effects 0.000 claims description 4
229960002086 dextran Drugs 0.000 claims description 4
KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 claims description 4
229960001123 epoprostenol Drugs 0.000 claims description 4
230000002209 hydrophobic effect Effects 0.000 claims description 4
FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims description 4
229920006209 poly(L-lactide-co-D,L-lactide) Polymers 0.000 claims description 4
229920001490 poly(butyl methacrylate) polymer Polymers 0.000 claims description 4
239000005015 poly(hydroxybutyrate) Substances 0.000 claims description 4
229920000058 polyacrylate Polymers 0.000 claims description 4
229920001610 polycaprolactone Polymers 0.000 claims description 4
229920000193 polymethacrylate Polymers 0.000 claims description 4
PUDHBTGHUJUUFI-SCTWWAJVSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-n-[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2r)-2-amino-3-naphthalen-2-ylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-p Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 PUDHBTGHUJUUFI-SCTWWAJVSA-N 0.000 claims description 3
GQGRDYWMOPRROR-ZIFKCHSBSA-N (e)-7-[(1r,2r,3s,5s)-3-hydroxy-5-[(4-phenylphenyl)methoxy]-2-piperidin-1-ylcyclopentyl]hept-4-enoic acid Chemical compound O([C@H]1C[C@@H]([C@@H]([C@H]1CC\C=C\CCC(O)=O)N1CCCCC1)O)CC(C=C1)=CC=C1C1=CC=CC=C1 GQGRDYWMOPRROR-ZIFKCHSBSA-N 0.000 claims description 3
SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 claims description 3
MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 claims description 3
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 3
102000007625 Hirudins Human genes 0.000 claims description 3
108010007267 Hirudins Proteins 0.000 claims description 3
102100025306 Integrin alpha-IIb Human genes 0.000 claims description 3
102000008607 Integrin beta3 Human genes 0.000 claims description 3
108010020950 Integrin beta3 Proteins 0.000 claims description 3
102000006992 Interferon-alpha Human genes 0.000 claims description 3
108010047761 Interferon-alpha Proteins 0.000 claims description 3
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 3
108010007859 Lisinopril Proteins 0.000 claims description 3
229930192392 Mitomycin Natural products 0.000 claims description 3
PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims description 3
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 3
ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 3
229930012538 Paclitaxel Natural products 0.000 claims description 3
108010035030 Platelet Membrane Glycoprotein IIb Proteins 0.000 claims description 3
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 3
108090000190 Thrombin Proteins 0.000 claims description 3
JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims description 3
239000000739 antihistaminic agent Substances 0.000 claims description 3
YEESUBCSWGVPCE-UHFFFAOYSA-N azanylidyneoxidanium iron(2+) pentacyanide Chemical compound [Fe++].[C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.N#[O+] YEESUBCSWGVPCE-UHFFFAOYSA-N 0.000 claims description 3
LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims description 3
229960002170 azathioprine Drugs 0.000 claims description 3
FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 claims description 3
229960000830 captopril Drugs 0.000 claims description 3
229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 claims description 3
HHHKFGXWKKUNCY-FHWLQOOXSA-N cilazapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N2[C@@H](CCCN2CCC1)C(O)=O)=O)CC1=CC=CC=C1 HHHKFGXWKKUNCY-FHWLQOOXSA-N 0.000 claims description 3
229960005025 cilazapril Drugs 0.000 claims description 3
229960001338 colchicine Drugs 0.000 claims description 3
OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 claims description 3
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 3
229960003957 dexamethasone Drugs 0.000 claims description 3
229960003668 docetaxel Drugs 0.000 claims description 3
229960002918 doxorubicin hydrochloride Drugs 0.000 claims description 3
210000002919 epithelial cell Anatomy 0.000 claims description 3
229960002949 fluorouracil Drugs 0.000 claims description 3
229960002897 heparin Drugs 0.000 claims description 3
ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 claims description 3
229940006607 hirudin Drugs 0.000 claims description 3
239000003112 inhibitor Substances 0.000 claims description 3
229960002437 lanreotide Drugs 0.000 claims description 3
108010021336 lanreotide Proteins 0.000 claims description 3
229960002394 lisinopril Drugs 0.000 claims description 3
RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 claims description 3
PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims description 3
229960004844 lovastatin Drugs 0.000 claims description 3
QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims description 3
229960000485 methotrexate Drugs 0.000 claims description 3
229960004857 mitomycin Drugs 0.000 claims description 3
HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 claims description 3
229960001597 nifedipine Drugs 0.000 claims description 3
229960002460 nitroprusside Drugs 0.000 claims description 3
229940012843 omega-3 fatty acid Drugs 0.000 claims description 3
235000020660 omega-3 fatty acid Nutrition 0.000 claims description 3
229960001592 paclitaxel Drugs 0.000 claims description 3
HIANJWSAHKJQTH-UHFFFAOYSA-N pemirolast Chemical compound CC1=CC=CN(C2=O)C1=NC=C2C=1N=NNN=1 HIANJWSAHKJQTH-UHFFFAOYSA-N 0.000 claims description 3
239000002571 phosphodiesterase inhibitor Substances 0.000 claims description 3
229920001434 poly(D-lactide) Polymers 0.000 claims description 3
229920000218 poly(hydroxyvalerate) Polymers 0.000 claims description 3
229910052700 potassium Inorganic materials 0.000 claims description 3
239000011591 potassium Substances 0.000 claims description 3
239000002089 prostaglandin antagonist Substances 0.000 claims description 3
229940076279 serotonin Drugs 0.000 claims description 3
150000003431 steroids Chemical class 0.000 claims description 3
SKIVFJLNDNKQPD-UHFFFAOYSA-N sulfacetamide Chemical compound CC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 SKIVFJLNDNKQPD-UHFFFAOYSA-N 0.000 claims description 3
229960005314 suramin Drugs 0.000 claims description 3
FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 claims description 3
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 3
229960004072 thrombin Drugs 0.000 claims description 3
YWBFPKPWMSWWEA-UHFFFAOYSA-O triazolopyrimidine Chemical compound BrC1=CC=CC(C=2N=C3N=CN[N+]3=C(NCC=3C=CN=CC=3)C=2)=C1 YWBFPKPWMSWWEA-UHFFFAOYSA-O 0.000 claims description 3
229950007952 vapiprost Drugs 0.000 claims description 3
229960003048 vinblastine Drugs 0.000 claims description 3
JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims description 3
229960004528 vincristine Drugs 0.000 claims description 3
OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 3
OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 3
KWPACVJPAFGBEQ-IKGGRYGDSA-N (2s)-1-[(2r)-2-amino-3-phenylpropanoyl]-n-[(3s)-1-chloro-6-(diaminomethylideneamino)-2-oxohexan-3-yl]pyrrolidine-2-carboxamide Chemical compound C([C@@H](N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)CCl)C1=CC=CC=C1 KWPACVJPAFGBEQ-IKGGRYGDSA-N 0.000 claims description 2
KZNRNQGTVRTDPN-UHFFFAOYSA-N 2-chloro-1,4-dimethylbenzene Chemical group CC1=CC=C(C)C(Cl)=C1 KZNRNQGTVRTDPN-UHFFFAOYSA-N 0.000 claims description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
239000000556 agonist Substances 0.000 claims description 2
IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 claims description 2
229960002768 dipyridamole Drugs 0.000 claims description 2
235000021323 fish oil Nutrition 0.000 claims description 2
239000002628 heparin derivative Substances 0.000 claims description 2
239000002464 receptor antagonist Substances 0.000 claims description 2
229940044551 receptor antagonist Drugs 0.000 claims description 2
229910052708 sodium Inorganic materials 0.000 claims description 2
239000011734 sodium Substances 0.000 claims description 2
229940083542 sodium Drugs 0.000 claims description 2
125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 claims 2
FYIBGDKNYYMMAG-UHFFFAOYSA-N ethane-1,2-diol;terephthalic acid Chemical compound OCCO.OC(=O)C1=CC=C(C(O)=O)C=C1 FYIBGDKNYYMMAG-UHFFFAOYSA-N 0.000 claims 1
239000006014 omega-3 oil Substances 0.000 claims 1
239000010410 layer Substances 0.000 description 46
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 33
201000010099 disease Diseases 0.000 description 18
208000035475 disorder Diseases 0.000 description 15
238000000034 method Methods 0.000 description 14
210000001367 artery Anatomy 0.000 description 12
230000015556 catabolic process Effects 0.000 description 12
238000006731 degradation reaction Methods 0.000 description 12
208000037803 restenosis Diseases 0.000 description 11
239000000126 substance Substances 0.000 description 11
210000005166 vasculature Anatomy 0.000 description 10
239000007857 degradation product Substances 0.000 description 9
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 8
230000009286 beneficial effect Effects 0.000 description 8
210000001519 tissue Anatomy 0.000 description 8
238000006065 biodegradation reaction Methods 0.000 description 7
239000011159 matrix material Substances 0.000 description 7
230000002792 vascular Effects 0.000 description 7
108090000790 Enzymes Proteins 0.000 description 6
102000004190 Enzymes Human genes 0.000 description 6
239000002253 acid Substances 0.000 description 6
229940088598 enzyme Drugs 0.000 description 6
238000001727 in vivo Methods 0.000 description 6
229940127215 low-molecular weight heparin Drugs 0.000 description 6
229920000747 poly(lactic acid) Polymers 0.000 description 6
206010003210 Arteriosclerosis Diseases 0.000 description 5
201000001320 Atherosclerosis Diseases 0.000 description 5
208000037260 Atherosclerotic Plaque Diseases 0.000 description 5
229920001577 copolymer Polymers 0.000 description 5
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 5
239000000463 material Substances 0.000 description 5
239000010935 stainless steel Substances 0.000 description 5
229910001220 stainless steel Inorganic materials 0.000 description 5
208000019553 vascular disease Diseases 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
208000007536 Thrombosis Diseases 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
239000008280 blood Substances 0.000 description 4
210000004369 blood Anatomy 0.000 description 4
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
230000000694 effects Effects 0.000 description 4
210000002216 heart Anatomy 0.000 description 4
229910052751 metal Inorganic materials 0.000 description 4
239000002184 metal Substances 0.000 description 4
239000000203 mixture Substances 0.000 description 4
239000000178 monomer Substances 0.000 description 4
230000002093 peripheral effect Effects 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 3
102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 3
238000010521 absorption reaction Methods 0.000 description 3
150000007513 acids Chemical class 0.000 description 3
229910045601 alloy Inorganic materials 0.000 description 3
239000000956 alloy Substances 0.000 description 3
238000002399 angioplasty Methods 0.000 description 3
239000005557 antagonist Substances 0.000 description 3
239000003146 anticoagulant agent Substances 0.000 description 3
238000005844 autocatalytic reaction Methods 0.000 description 3
230000008901 benefit Effects 0.000 description 3
210000004556 brain Anatomy 0.000 description 3
210000001736 capillary Anatomy 0.000 description 3
210000001715 carotid artery Anatomy 0.000 description 3
150000004676 glycans Polymers 0.000 description 3
239000004310 lactic acid Substances 0.000 description 3
230000007246 mechanism Effects 0.000 description 3
210000000056 organ Anatomy 0.000 description 3
239000002245 particle Substances 0.000 description 3
230000035699 permeability Effects 0.000 description 3
230000035755 proliferation Effects 0.000 description 3
239000000758 substrate Substances 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
208000032843 Hemorrhage Diseases 0.000 description 2
JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
208000031481 Pathologic Constriction Diseases 0.000 description 2
239000002246 antineoplastic agent Substances 0.000 description 2
210000000617 arm Anatomy 0.000 description 2
WERYXYBDKMZEQL-UHFFFAOYSA-N butane-1,4-diol Chemical compound OCCCCO WERYXYBDKMZEQL-UHFFFAOYSA-N 0.000 description 2
150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
210000000748 cardiovascular system Anatomy 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
235000012000 cholesterol Nutrition 0.000 description 2
239000011247 coating layer Substances 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
210000004351 coronary vessel Anatomy 0.000 description 2
CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 2
238000009792 diffusion process Methods 0.000 description 2
238000001647 drug administration Methods 0.000 description 2
238000012377 drug delivery Methods 0.000 description 2
210000001105 femoral artery Anatomy 0.000 description 2
239000012634 fragment Substances 0.000 description 2
230000036541 health Effects 0.000 description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
230000008105 immune reaction Effects 0.000 description 2
238000002513 implantation Methods 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
235000014655 lactic acid Nutrition 0.000 description 2
JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 2
210000002414 leg Anatomy 0.000 description 2
238000005259 measurement Methods 0.000 description 2
208000010125 myocardial infarction Diseases 0.000 description 2
239000002105 nanoparticle Substances 0.000 description 2
229910001000 nickel titanium Inorganic materials 0.000 description 2
230000035515 penetration Effects 0.000 description 2
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
229920006149 polyester-amide block copolymer Polymers 0.000 description 2
229920001451 polypropylene glycol Polymers 0.000 description 2
229920001282 polysaccharide Polymers 0.000 description 2
239000005017 polysaccharide Substances 0.000 description 2
229920001296 polysiloxane Polymers 0.000 description 2
239000000047 product Substances 0.000 description 2
239000007787 solid Substances 0.000 description 2
208000037804 stenosis Diseases 0.000 description 2
230000036262 stenosis Effects 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
YYSFXUWWPNHNAZ-PKJQJFMNSA-N umirolimus Chemical compound C1[C@@H](OC)[C@H](OCCOCC)CC[C@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 YYSFXUWWPNHNAZ-PKJQJFMNSA-N 0.000 description 2
210000003462 vein Anatomy 0.000 description 2
239000002699 waste material Substances 0.000 description 2
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
AJBMORBNKXNZSF-COSHMZDQSA-N (2s,3s,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3s,4s,5r,6r)-2-carboxy-4,5-dimethoxy-6-[(2r,3r,4s,5r,6s)-6-methoxy-4,5-disulfooxy-2-(sulfooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-disulfooxy-2-(sulfooxymethyl)oxan-3-yl]oxy-4,5-dimethoxy-3-[(2r,3r,4s,5r,6r)-3,4 Chemical compound OS(=O)(=O)O[C@@H]1[C@@H](OS(O)(=O)=O)[C@@H](OC)O[C@H](COS(O)(=O)=O)[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@H](O[C@H]3[C@@H]([C@@H](OC)[C@H](O[C@@H]4[C@@H]([C@@H](OC)[C@H](OC)[C@@H](COS(O)(=O)=O)O4)OC)[C@H](O3)C(O)=O)OC)[C@@H](COS(O)(=O)=O)O2)OS(O)(=O)=O)[C@H](C(O)=O)O1 AJBMORBNKXNZSF-COSHMZDQSA-N 0.000 description 1
229920002818 (Hydroxyethyl)methacrylate Polymers 0.000 description 1
RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 1
SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
VRBFTYUMFJWSJY-UHFFFAOYSA-N 28804-46-8 Chemical compound ClC1CC(C=C2)=CC=C2C(Cl)CC2=CC=C1C=C2 VRBFTYUMFJWSJY-UHFFFAOYSA-N 0.000 description 1
QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 1
GNSFRPWPOGYVLO-UHFFFAOYSA-N 3-hydroxypropyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCCO GNSFRPWPOGYVLO-UHFFFAOYSA-N 0.000 description 1
YFICSDVNKFLZRQ-UHFFFAOYSA-N 3-trimethylsilylpropyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCC[Si](C)(C)C YFICSDVNKFLZRQ-UHFFFAOYSA-N 0.000 description 1
YSFGBPCBPNVLOK-UHFFFAOYSA-N 6-hydroxy-2-methylhex-2-enamide Chemical compound NC(=O)C(C)=CCCCO YSFGBPCBPNVLOK-UHFFFAOYSA-N 0.000 description 1
FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
239000005541 ACE inhibitor Substances 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
206010002329 Aneurysm Diseases 0.000 description 1
206010056375 Bile duct obstruction Diseases 0.000 description 1
229940127291 Calcium channel antagonist Drugs 0.000 description 1
208000014882 Carotid artery disease Diseases 0.000 description 1
229920001661 Chitosan Polymers 0.000 description 1
206010008635 Cholestasis Diseases 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
229930182843 D-Lactic acid Natural products 0.000 description 1
JVTAAEKCZFNVCJ-UWTATZPHSA-N D-lactic acid Chemical compound C[C@@H](O)C(O)=O JVTAAEKCZFNVCJ-UWTATZPHSA-N 0.000 description 1
229920001353 Dextrin Polymers 0.000 description 1
239000004375 Dextrin Substances 0.000 description 1
102000016942 Elastin Human genes 0.000 description 1
108010014258 Elastin Proteins 0.000 description 1
206010072064 Exposure to body fluid Diseases 0.000 description 1
108010073385 Fibrin Proteins 0.000 description 1
102000009123 Fibrin Human genes 0.000 description 1
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
108010049003 Fibrinogen Proteins 0.000 description 1
102000008946 Fibrinogen Human genes 0.000 description 1
229920002683 Glycosaminoglycan Polymers 0.000 description 1
WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 1
206010022562 Intermittent claudication Diseases 0.000 description 1
CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
208000016222 Pancreatic disease Diseases 0.000 description 1
208000005764 Peripheral Arterial Disease Diseases 0.000 description 1
208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 1
NTUPOKHATNSWCY-JYJNAYRXSA-N Phe-Pro-Arg Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)C1=CC=CC=C1 NTUPOKHATNSWCY-JYJNAYRXSA-N 0.000 description 1
229910000566 Platinum-iridium alloy Inorganic materials 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
229920002732 Polyanhydride Polymers 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
229920001710 Polyorthoester Polymers 0.000 description 1
229920002396 Polyurea Polymers 0.000 description 1
241000736029 Ruvettus pretiosus Species 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
108010000499 Thromboplastin Proteins 0.000 description 1
102000002262 Thromboplastin Human genes 0.000 description 1
206010046406 Ureteric obstruction Diseases 0.000 description 1
208000024248 Vascular System injury Diseases 0.000 description 1
208000012339 Vascular injury Diseases 0.000 description 1
QYKIQEUNHZKYBP-UHFFFAOYSA-N Vinyl ether Chemical class C=COC=C QYKIQEUNHZKYBP-UHFFFAOYSA-N 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
WAIPAZQMEIHHTJ-UHFFFAOYSA-N [Cr].[Co] Chemical class [Cr].[Co] WAIPAZQMEIHHTJ-UHFFFAOYSA-N 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
230000001464 adherent effect Effects 0.000 description 1
229940072056 alginate Drugs 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000180 alkyd Polymers 0.000 description 1
229920006125 amorphous polymer Polymers 0.000 description 1
230000003872 anastomosis Effects 0.000 description 1
229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
238000000137 annealing Methods 0.000 description 1
230000002744 anti-aggregatory effect Effects 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
230000000118 anti-neoplastic effect Effects 0.000 description 1
239000000043 antiallergic agent Substances 0.000 description 1
229940127219 anticoagulant drug Drugs 0.000 description 1
230000010100 anticoagulation Effects 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
239000003080 antimitotic agent Substances 0.000 description 1
229940034982 antineoplastic agent Drugs 0.000 description 1
239000004019 antithrombin Substances 0.000 description 1
229960004676 antithrombotic agent Drugs 0.000 description 1
210000000709 aorta Anatomy 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
210000000013 bile duct Anatomy 0.000 description 1
239000000560 biocompatible material Substances 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
229920001400 block copolymer Polymers 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
210000000621 bronchi Anatomy 0.000 description 1
230000001680 brushing effect Effects 0.000 description 1
239000000480 calcium channel blocker Substances 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
210000001175 cerebrospinal fluid Anatomy 0.000 description 1
230000008859 change Effects 0.000 description 1
BULLHNJGPPOUOX-UHFFFAOYSA-N chloroacetone Chemical compound CC(=O)CCl BULLHNJGPPOUOX-UHFFFAOYSA-N 0.000 description 1
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
229960001231 choline Drugs 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
208000024980 claudication Diseases 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
229960002842 clobetasol Drugs 0.000 description 1
CBGUOGMQLZIXBE-XGQKBEPLSA-N clobetasol propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CBGUOGMQLZIXBE-XGQKBEPLSA-N 0.000 description 1
NVIVJPRCKQTWLY-UHFFFAOYSA-N cobalt nickel Chemical compound [Co][Ni][Co] NVIVJPRCKQTWLY-UHFFFAOYSA-N 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
230000001010 compromised effect Effects 0.000 description 1
238000010276 construction Methods 0.000 description 1
239000000599 controlled substance Substances 0.000 description 1
238000010411 cooking Methods 0.000 description 1
208000029078 coronary artery disease Diseases 0.000 description 1
239000013078 crystal Substances 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
239000000824 cytostatic agent Substances 0.000 description 1
230000001085 cytostatic effect Effects 0.000 description 1
229940022769 d- lactic acid Drugs 0.000 description 1
230000006378 damage Effects 0.000 description 1
229960004776 danaparoid sodium Drugs 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
230000001934 delay Effects 0.000 description 1
230000008021 deposition Effects 0.000 description 1
230000001627 detrimental effect Effects 0.000 description 1
235000019425 dextrin Nutrition 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
238000002405 diagnostic procedure Methods 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
210000000188 diaphragm Anatomy 0.000 description 1
230000010339 dilation Effects 0.000 description 1
230000006806 disease prevention Effects 0.000 description 1
238000002224 dissection Methods 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
229920002549 elastin Polymers 0.000 description 1
239000002659 electrodeposit Substances 0.000 description 1
229910000701 elgiloys (Co-Cr-Ni Alloy) Inorganic materials 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
239000003822 epoxy resin Substances 0.000 description 1
210000003238 esophagus Anatomy 0.000 description 1
125000004185 ester group Chemical group 0.000 description 1
RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
238000001125 extrusion Methods 0.000 description 1
229950003499 fibrin Drugs 0.000 description 1
229940012952 fibrinogen Drugs 0.000 description 1
KANJSNBRCNMZMV-ABRZTLGGSA-N fondaparinux Chemical compound O[C@@H]1[C@@H](NS(O)(=O)=O)[C@@H](OC)O[C@H](COS(O)(=O)=O)[C@H]1O[C@H]1[C@H](OS(O)(=O)=O)[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O[C@@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O4)NS(O)(=O)=O)[C@H](O3)C(O)=O)O)[C@@H](COS(O)(=O)=O)O2)NS(O)(=O)=O)[C@H](C(O)=O)O1 KANJSNBRCNMZMV-ABRZTLGGSA-N 0.000 description 1
229960001318 fondaparinux Drugs 0.000 description 1
238000013467 fragmentation Methods 0.000 description 1
238000006062 fragmentation reaction Methods 0.000 description 1
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
229910052737 gold Inorganic materials 0.000 description 1
239000010931 gold Substances 0.000 description 1
LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 1
210000003709 heart valve Anatomy 0.000 description 1
230000002008 hemorrhagic effect Effects 0.000 description 1
239000008241 heterogeneous mixture Substances 0.000 description 1
229920002674 hyaluronan Polymers 0.000 description 1
229960003160 hyaluronic acid Drugs 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
206010020718 hyperplasia Diseases 0.000 description 1
210000003090 iliac artery Anatomy 0.000 description 1
238000007654 immersion Methods 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
239000007943 implant Substances 0.000 description 1
208000014674 injury Diseases 0.000 description 1
229950000038 interferon alfa Drugs 0.000 description 1
125000003010 ionic group Chemical group 0.000 description 1
150000002605 large molecules Chemical class 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
239000002502 liposome Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
238000002483 medication Methods 0.000 description 1
QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
229910052753 mercury Inorganic materials 0.000 description 1
239000007769 metal material Substances 0.000 description 1
150000002739 metals Chemical class 0.000 description 1
VUZPPFZMUPKLLV-UHFFFAOYSA-N methane;hydrate Chemical compound C.O VUZPPFZMUPKLLV-UHFFFAOYSA-N 0.000 description 1
239000011859 microparticle Substances 0.000 description 1
239000004005 microsphere Substances 0.000 description 1
238000000465 moulding Methods 0.000 description 1
239000002077 nanosphere Substances 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
HLXZNVUGXRDIFK-UHFFFAOYSA-N nickel titanium Chemical compound [Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni] HLXZNVUGXRDIFK-UHFFFAOYSA-N 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
230000001453 nonthrombogenic effect Effects 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
230000000149 penetrating effect Effects 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
YHHSONZFOIEMCP-UHFFFAOYSA-O phosphocholine Chemical compound C[N+](C)(C)CCOP(O)(O)=O YHHSONZFOIEMCP-UHFFFAOYSA-O 0.000 description 1
229950004354 phosphorylcholine Drugs 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
229910052697 platinum Inorganic materials 0.000 description 1
HWLDNSXPUQTBOD-UHFFFAOYSA-N platinum-iridium alloy Chemical class [Ir].[Pt] HWLDNSXPUQTBOD-UHFFFAOYSA-N 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
229920000233 poly(alkylene oxides) Polymers 0.000 description 1
229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
229920002627 poly(phosphazenes) Polymers 0.000 description 1
229920002239 polyacrylonitrile Polymers 0.000 description 1
229920001707 polybutylene terephthalate Polymers 0.000 description 1
229920000647 polyepoxide Polymers 0.000 description 1
229920000570 polyether Polymers 0.000 description 1
238000012667 polymer degradation Methods 0.000 description 1
239000013047 polymeric layer Substances 0.000 description 1
239000004926 polymethyl methacrylate Substances 0.000 description 1
229920000098 polyolefin Polymers 0.000 description 1
150000004804 polysaccharides Polymers 0.000 description 1
229920002635 polyurethane Polymers 0.000 description 1
239000004814 polyurethane Substances 0.000 description 1
229920001290 polyvinyl ester Polymers 0.000 description 1
229920001291 polyvinyl halide Polymers 0.000 description 1
229920006214 polyvinylidene halide Polymers 0.000 description 1
210000003137 popliteal artery Anatomy 0.000 description 1
239000011148 porous material Substances 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
238000011160 research Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
238000007761 roller coating Methods 0.000 description 1
230000007017 scission Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
239000002356 single layer Substances 0.000 description 1
229940126586 small molecule drug Drugs 0.000 description 1
210000000329 smooth muscle myocyte Anatomy 0.000 description 1
239000002904 solvent Substances 0.000 description 1
210000005070 sphincter Anatomy 0.000 description 1
238000005507 spraying Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
229960001967 tacrolimus Drugs 0.000 description 1
QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
229910052715 tantalum Inorganic materials 0.000 description 1
GUVRBAGPIYLISA-UHFFFAOYSA-N tantalum atom Chemical compound [Ta] GUVRBAGPIYLISA-UHFFFAOYSA-N 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
210000003437 trachea Anatomy 0.000 description 1
230000004102 tricarboxylic acid cycle Effects 0.000 description 1
210000004026 tunica intima Anatomy 0.000 description 1
210000003932 urinary bladder Anatomy 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1
230000036642 wellbeing Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
- A61L27/34—Macromolecular materials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/58—Materials at least partially resorbable by the body
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/10—Macromolecular materials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/148—Materials at least partially resorbable by the body
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/606—Coatings

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Vascular Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Dermatology (AREA)
Surgery (AREA)
Oral & Maxillofacial Surgery (AREA)
Transplantation (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicinal Preparation (AREA)
Materials For Medical Uses (AREA)
Infusion, Injection, And Reservoir Apparatuses (AREA)
Media Introduction/Drainage Providing Device (AREA)
External Artificial Organs (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Prostheses (AREA)

ES07717043.9T 2006-02-10 2007-01-26 Dispositivo médico implantable con revestimiento de suministro de fármacos de poliéster de erosión superficial Active ES2451653T3 (es)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US351598		2006-02-10
US11/351,598 US8021678B2 (en)	2006-02-10	2006-02-10	Implantable medical device with polymer coating in a surface area to volume ratio providing surface erosion characteristics
PCT/US2007/002126 WO2007094940A2 (en)	2006-02-10	2007-01-26	Implantable medical device with surface-eroding polyester drug delivery coating

Publications (1)

Publication Number	Publication Date
ES2451653T3 true ES2451653T3 (es)	2014-03-28

Family

ID=38284002

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ES07717043.9T Active ES2451653T3 (es)	2006-02-10	2007-01-26	Dispositivo médico implantable con revestimiento de suministro de fármacos de poliéster de erosión superficial

Country Status (10)

Country	Link
US (1)	US8021678B2 (pl)
EP (1)	EP1986711B1 (pl)
JP (1)	JP2009525809A (pl)
CY (1)	CY1115092T1 (pl)
DK (1)	DK1986711T3 (pl)
ES (1)	ES2451653T3 (pl)
PL (1)	PL1986711T3 (pl)
PT (1)	PT1986711E (pl)
SI (1)	SI1986711T1 (pl)
WO (1)	WO2007094940A2 (pl)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US10076641B2 (en)	2005-05-11	2018-09-18	The Spectranetics Corporation	Methods and systems for delivering substances into luminal walls
US7910152B2 (en) *	2006-02-28	2011-03-22	Advanced Cardiovascular Systems, Inc.	Poly(ester amide)-based drug delivery systems with controlled release rate and morphology
US8323676B2 (en) *	2008-06-30	2012-12-04	Abbott Cardiovascular Systems Inc.	Poly(ester-amide) and poly(amide) coatings for implantable medical devices for controlled release of a protein or peptide and a hydrophobic drug
US8414526B2 (en)	2006-11-20	2013-04-09	Lutonix, Inc.	Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US8430055B2 (en)	2008-08-29	2013-04-30	Lutonix, Inc.	Methods and apparatuses for coating balloon catheters
US8414525B2 (en)	2006-11-20	2013-04-09	Lutonix, Inc.	Drug releasing coatings for medical devices
US8414910B2 (en)	2006-11-20	2013-04-09	Lutonix, Inc.	Drug releasing coatings for medical devices
US20080276935A1 (en)	2006-11-20	2008-11-13	Lixiao Wang	Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US8414909B2 (en)	2006-11-20	2013-04-09	Lutonix, Inc.	Drug releasing coatings for medical devices
US9700704B2 (en)	2006-11-20	2017-07-11	Lutonix, Inc.	Drug releasing coatings for balloon catheters
US9737640B2 (en)	2006-11-20	2017-08-22	Lutonix, Inc.	Drug releasing coatings for medical devices
US8998846B2 (en)	2006-11-20	2015-04-07	Lutonix, Inc.	Drug releasing coatings for balloon catheters
US8425459B2 (en)	2006-11-20	2013-04-23	Lutonix, Inc.	Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US20090104240A1 (en) *	2007-10-19	2009-04-23	Abbott Cardiovascular Systems Inc.	Dual Drug Formulations For Implantable Medical Devices For Treatment of Vascular Diseases
CA2703017C (en) *	2007-10-19	2017-04-25	Roseita Esfand	Self-eliminating coatings
US20090111787A1 (en) *	2007-10-31	2009-04-30	Florencia Lim	Polymer blends for drug delivery stent matrix with improved thermal stability
US8580801B2 (en)	2008-07-23	2013-11-12	Robert I. Henkin	Phosphodiesterase inhibitor treatment
US20100047319A1 (en) *	2008-08-21	2010-02-25	Michael Huy Ngo	Biodegradable Poly(Ester-Amide) And Poly(Amide) Coatings For Implantable Medical Devices With Enhanced Bioabsorption Times
US9198968B2 (en) *	2008-09-15	2015-12-01	The Spectranetics Corporation	Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US8257722B2 (en) *	2008-09-15	2012-09-04	Cv Ingenuity Corp.	Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US8128951B2 (en)	2008-09-15	2012-03-06	Cv Ingenuity Corp.	Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US8114429B2 (en)	2008-09-15	2012-02-14	Cv Ingenuity Corp.	Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US8092822B2 (en)	2008-09-29	2012-01-10	Abbott Cardiovascular Systems Inc.	Coatings including dexamethasone derivatives and analogs and olimus drugs
US20100092534A1 (en) *	2008-10-10	2010-04-15	Medtronic Vascular, Inc.	Combination Local Delivery Using a Stent
CN102933658A (zh)	2009-12-18	2013-02-13	界面生物公司	从自组装涂层局部递送药物
US8685433B2 (en)	2010-03-31	2014-04-01	Abbott Cardiovascular Systems Inc.	Absorbable coating for implantable device
EP2380604A1 (en)	2010-04-19	2011-10-26	InnoRa Gmbh	Improved coating formulations for scoring or cutting balloon catheters
US20120100187A1 (en) *	2010-10-26	2012-04-26	Surmodics, Inc.	Coatings and methods for controlled elution of hydrophilic active agents
ES2574522T3 (es) *	2012-06-08	2016-06-20	Biotronik Ag	Ésteres 40-O-hidrocarburo cíclico de rapamicina, composiciones y procedimientos
US9956385B2 (en)	2012-06-28	2018-05-01	The Spectranetics Corporation	Post-processing of a medical device to control morphology and mechanical properties
NL2010830C2 (en) *	2013-05-21	2014-11-26	Alvimedica Vascular Res B V	Method and device for depositing a material on a target and medical device obstainable therewith.
US10525171B2 (en)	2014-01-24	2020-01-07	The Spectranetics Corporation	Coatings for medical devices
US10598672B2 (en)	2014-02-18	2020-03-24	Cyrano Therapeutics, Inc.	Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell
US20210154372A1 (en) *	2017-05-15	2021-05-27	C.R. Bard, Inc.	Medical device with drug-eluting coating and intermediate layer
JP2021531061A (ja)	2018-05-22	2021-11-18	インターフェースバイオロジクス，インコーポレーテッド	薬物を脈管壁に送達するための組成物及び方法
EP3880266B1 (en) *	2018-11-14	2025-05-07	Lutonix, Inc.	Medical device with drug-eluting coating on modified device surface
JP7606530B2 (ja)	2020-03-24	2024-12-25	シラノセラピューティクス，インコーポレイテッド	コロナウイルス感染症による化学感覚機能障害の治療
US12383246B2 (en)	2020-10-12	2025-08-12	Abbott Cardiovascular Systems, Inc.	Vessel closure device with improved safety and tract hemostasis
WO2023122469A2 (en) *	2021-12-21	2023-06-29	Cyrano Therapeutics, Inc.	Implants for loss of taste and smell

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5512600A (en) *	1993-01-15	1996-04-30	Massachusetts Institute Of Technology	Preparation of bonded fiber structures for cell implantation
US6926919B1 (en) *	2003-02-26	2005-08-09	Advanced Cardiovascular Systems, Inc.	Method for fabricating a coating for a medical device
US20070117959A1 (en)	2003-12-15	2007-05-24	The Children's Hospital Of Philadelphia	Novel polyesters
RU2363497C2 (ru)	2003-12-24	2009-08-10	Новартис Аг	Фармацевтические композиции
US20060041102A1 (en)	2004-08-23	2006-02-23	Advanced Cardiovascular Systems, Inc.	Implantable devices comprising biologically absorbable polymers having constant rate of degradation and methods for fabricating the same

2006
- 2006-02-10 US US11/351,598 patent/US8021678B2/en active Active
2007
- 2007-01-26 JP JP2008554255A patent/JP2009525809A/ja active Pending
- 2007-01-26 SI SI200731454T patent/SI1986711T1/sl unknown
- 2007-01-26 DK DK07717043.9T patent/DK1986711T3/en active
- 2007-01-26 EP EP07717043.9A patent/EP1986711B1/en not_active Revoked
- 2007-01-26 ES ES07717043.9T patent/ES2451653T3/es active Active
- 2007-01-26 WO PCT/US2007/002126 patent/WO2007094940A2/en not_active Ceased
- 2007-01-26 PL PL07717043T patent/PL1986711T3/pl unknown
- 2007-01-26 PT PT77170439T patent/PT1986711E/pt unknown
2014
- 2014-05-15 CY CY20141100354T patent/CY1115092T1/el unknown

Also Published As

Publication number	Publication date
PL1986711T3 (pl)	2014-09-30
SI1986711T1 (sl)	2014-06-30
WO2007094940A3 (en)	2008-01-10
PT1986711E (pt)	2014-03-20
CY1115092T1 (el)	2016-12-14
US20070190103A1 (en)	2007-08-16
EP1986711B1 (en)	2014-03-05
WO2007094940A2 (en)	2007-08-23
JP2009525809A (ja)	2009-07-16
DK1986711T3 (en)	2014-03-17
EP1986711A2 (en)	2008-11-05
US8021678B2 (en)	2011-09-20

Publication	Publication Date	Title
ES2451653T3 (es)	2014-03-28	Dispositivo médico implantable con revestimiento de suministro de fármacos de poliéster de erosión superficial
JP5701497B2 (ja)	2015-04-15	ステントの分解を調節し、ｐＨを中性に維持するためのコーティングを有する吸収性ステント
EP2046410B1 (de)	2019-04-10	Herstellung, verfahren und verwendung von wirkstofffreisetzenden medizinprodukten zur permanenten offenhaltung von blutgefässen
EP2731661B1 (en)	2019-09-18	Drug elution medical device
JP6955553B2 (ja)	2021-10-27	薬物溶出ステントおよび機能的内皮細胞層の回復を可能とするためのその使用方法
ES2454559T3 (es)	2014-04-10	Implante que comprende un revestimiento bioabsorbible con hidrofobicidad regulada
JP4617258B2 (ja)	2011-01-19	被検者の体内で使用される生体適合性ステントの製造方法
ES2479193T3 (es)	2014-07-23	Revestimientos incluyendo acetato de dexametasona y fármacos olimus
JP5816666B2 (ja)	2015-11-18	電気グラフト化されたプライマー被覆を付け、生物分解性放出層を備えた薬物溶離性ステント
JP5695107B2 (ja)	2015-04-01	ホスホリルコリン基を含有する共重合体とその製造及び利用方法
JP2012529922A (ja)	2012-11-29	ポリ（エチレングリコール）及びポリ（ラクチド−グリコリド）のブロックコポリマーを含む埋込型医療機器及びそのためのコーティング物
JP4588986B2 (ja)	2010-12-01	体内埋込医療器具
JP5542052B2 (ja)	2014-07-09	薄い吸収性コーティングを有する埋め込み型医療器具
ES2458225T3 (es)	2014-04-30	Revestimientos para dispositivos implantables que comprenden polímeros de ácido láctico y métodos para fabricar los mismos
JPWO2007116646A1 (ja)	2009-08-20	生体内留置物
ES2316935T3 (es)	2009-04-16	Dispositivos biomedicos con recubrimiento de polimeros.
KR20230150790A (ko)	2023-10-31	약물 용출 스텐트
JP2010155095A (ja)	2010-07-15	体内埋込医療器具
JP2004267283A (ja)	2004-09-30	体内埋込医療材料および体内埋込医療器具
CN117098517A (zh)	2023-11-21	药物洗脱支架